It's hard not to lose patience, when the company couldn't even complete the FDA submission after many assurances. Not sure what the latest snag might be. It is perhaps not so simple and it shows that the company lacks FDA expertise. Meanwhile, the cash position of the company has turned from solid to being shaky and slowly turning towards critical. A sense of urgency is needed, but unfortunately not observed so far.
- Forums
- ASX - By Stock
- GSS
- Ann: Quarterly update and Appendix 4C
GSS
genetic signatures limited
Add to My Watchlist
2.67%
!
36.5¢

Ann: Quarterly update and Appendix 4C, page-8
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
36.5¢ |
Change
-0.010(2.67%) |
Mkt cap ! $82.90M |
Open | High | Low | Value | Volume |
36.5¢ | 36.5¢ | 36.5¢ | $160 | 438 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 19601 | 36.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.5¢ | 32411 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 14601 | 0.365 |
2 | 9513 | 0.360 |
3 | 30509 | 0.350 |
1 | 1683 | 0.300 |
1 | 25000 | 0.270 |
Price($) | Vol. | No. |
---|---|---|
0.375 | 32411 | 1 |
0.380 | 3086 | 1 |
0.390 | 20000 | 1 |
0.395 | 5000 | 1 |
0.400 | 111918 | 2 |
Last trade - 13.38pm 04/07/2025 (20 minute delay) ? |
Featured News
GSS (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online